Fracture Prevention Clinical Studies
Our clinical studies group participates in multicentre international clinical trials evaluating potential osteoporosis treatments that are in the final stages of pharmaceutical development. We recruit patients and volunteers who have had a fracture or who have a family history of osteoporosis. Volunteer participants who meet specific risk criteria are randomly allocated to receive a new drug or various combinations of drugs.
Staff
 Clinical Trials Medical
OfficerDr Yvonne Selecki |
 Clinical Research AssociateDr Orit Wolstein |
News
Why measuring absolute risk of fracture could save many broken bones
MEDIA RELEASE:
28 Jul 2009
Garvan scientists stress the importance of measuring a person's absolute risk of fracture when determining their treatment options. Other factors currently determine whether or not the Australian Government will pay for preventative treatment.
Study shows that prostate cancer increases the risk of bone fracture
MEDIA RELEASE:
14 May 2008
As unlikely as it sounds, scientists at Garvan have shown that there is a link between prostate cancer and a higher risk of bone fracture. Their study suggests that men with prostate cancer face a 50% higher risk of fracture, which increases to nearly 100% if they are receiving androgen deprivation therapy for their prostate cancer.
Genotyping takes us closer to an osteoporosis fingerprint
MEDIA RELEASE:
30 Apr 2008
Garvan collaborated with the Icelandic genetics company, deCode, in an extensive multi-nation genome-wide search to find the genes linked to osteoporosis and fracture. Five regions of interest have been identified that appear to warrant further scientific investigation.
